Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it - Test2 - elhamkhani - TriplyDB

Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it

Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it

http://www.wikidata.org/entity/Q27489891

about

T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus Ebolavirus glycoprotein structure and mechanism of entry Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies Both Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like Domain Discovery of an antibody for pan-ebolavirus therapy Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion Antibody evasion by a gammaherpesvirus O-glycan shield Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge Therapeutics for filovirus infection: traditional approaches and progress towards in silico drug design.Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1.Structure-based vaccine design in HIV: blind men and the elephant?The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway.A thermostable, chromatographically purified Ebola nano-VLP vaccine.Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop Prediction and identification of mouse cytotoxic T lymphocyte epitopes in Ebola virus glycoproteins.Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.Potential vaccines and post-exposure treatments for filovirus infections.Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.Potent neutralizing monoclonal antibodies against Ebola virus infection Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking Protein engineering strategies for the development of viral vaccines and immunotherapeutics.Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.Chasing Ebola through the Endosomal Labyrinth.Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: stability and pH effects.Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.A new strategy for full-length Ebola virus glycoprotein expression in E.coli.The structural basis for filovirus neutralization by monoclonal antibodies Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs

P2860

Q24301153-C1EA916A-B062-41F0-9E88-B524B140F1DB Q27490991-5BBA0289-38A8-4731-B59B-15F31A18B4E5 Q27704173-0C333687-BF41-4573-A04F-5F5FCB73253B Q28596689-BC5B57A5-5647-4F41-8807-942E3DADF2C5 Q30385927-C495787C-B07F-4FDC-A574-248741EDA356 Q30426228-0A14C7D4-22D2-4D1C-AC4D-A952C38A1C55 Q34079366-1DCE250A-BBE7-4A4A-8145-15F597916F9E Q34082672-73CEDBA6-19CA-4B98-91D0-714F85847E16 Q34227510-34AEC86E-D2C3-4DDC-8060-40C3EFA92473 Q34361120-823EC439-CBDE-47A3-AD82-1C84D5DBB130 Q34371001-7FB8F4F2-94B1-4838-86ED-1F89B4AACE65 Q34443252-33A88897-686F-4FFB-9A2D-E84A1D4D16CD Q34987048-8E8169AD-5E4E-407A-934D-C92D26AF7E13 Q35226192-452E8963-9735-42B3-81A7-93734A908F87 Q35853669-832010B9-1060-4EEA-A8F7-4FB4F11F3E28 Q36043176-73999005-F4D4-4FDE-B761-2C65BB37565C Q36138983-D9E4C0F1-06CF-476D-BDE4-10800BEB6D04 Q36378625-65DCF349-407E-4590-85D1-DF91B7EFFA4E Q36404178-CA2312B7-6C7D-47A4-A638-F7E3B4238466 Q36414333-A7AB5226-510C-446C-90A8-29FAD64798AA Q36499251-512D9F00-5A6E-45BA-A524-39511A5C8CAD Q36903111-AB96B708-6294-4EA7-82EA-2EF3DF1F7547 Q36934038-5D09677D-069E-4172-946C-72D8A48AF700 Q37007013-A76CFDA4-60F4-4D24-8089-42A767BB023E Q37294380-4697FB17-BDDB-4F5C-92A9-47A1AF51B494 Q37625877-FF68C621-122B-4C54-B89B-72116F969770 Q37828538-FBE98806-8A7E-4EAD-86DA-BAFB448A2A0A Q38032879-2DE77B7D-9C38-4880-9543-BFDB8F7205B2 Q38560342-3EAB08CB-0666-4CF1-9EEE-972201D31BE6 Q38666508-D29B5D87-7148-49D3-9C8C-C90C4B4F560F Q40056179-24726338-8629-44C9-836E-FB67F50C1F70 Q40075725-E3FFC0A9-A84C-41C2-B55C-015D7D73D9CB Q56536340-E282152D-533F-4A3F-A0E7-65B70310918A Q56999931-3C35D43D-4867-47F2-A18C-0E12C7EA0B44 Q57197569-800F0C05-94D2-4FD6-901A-256D34700DF5

P2860

Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it

http://www.wikidata.org/entity/Q27489891

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@ast

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@en

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@nl

type

label

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@ast

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@en

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@nl

prefLabel

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@ast

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@en

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@nl

P1433

Q27489891-ED1200CD-B3D3-49D6-BD7C-B31CAB2FB0E3

P1476

Q27489891-C18FF2F4-9231-4718-BAF8-4FC548F4F50C

P2093

Q27489891-3C10CA64-80F5-46A0-B823-805A4229B24B

P2860

Q27489891-06B14174-CAF9-4D45-953B-99CEAE1B2558

Q27489891-08131C1C-115C-496B-B8B3-CE354A4E92C7

Q27489891-0BD4C3E6-2F1F-4BB9-9C4B-E3BE7FF89116

Q27489891-1174318F-2F1C-4D7A-B675-9D7748967E65

Q27489891-1BEEB083-E21E-41FB-8625-0F6AD23DF783

Q27489891-2BA67E7E-B20C-4F6B-8D55-D7B9CA8589CC

Q27489891-2D11BA40-7C46-4176-A4F1-910E4F6AB9AC

Q27489891-321FC0C1-EB4C-4204-9B1C-2A18AD147E2A

Q27489891-327573DE-A749-489B-9FA6-350ED439E663

Q27489891-393081DA-AB2C-40C5-B95C-A73FA6ABBDBB

P304

Q27489891-226963AF-A16F-41DE-BBC5-8AD50E3F2488

P31

Q27489891-56D89BC3-5B35-433D-821A-B772CCE9A8B4

P3181

Q27489891-89AB14C8-3639-4874-A934-3667D5558191

P356

Q27489891-4A5DF338-6E30-41D1-8211-A60859AA88FC

P433

Q27489891-1C8F34DB-BF5A-4828-925B-F22F4E72571E

P478

Q27489891-24137F57-CF30-441A-964A-F5059570ADE9

P50

Q27489891-CE0EB846-3213-4550-BE0C-7675A209008C

P577

Q27489891-30E3FC7A-07E4-4ABD-93E2-AB1D135DA1A6

P5875

Q27489891-54103C0C-9257-4E95-A2D5-2E3A80D98359

P698

Q27489891-A275A714-7C0B-4185-BE24-623BFBB85B06

P921

Q27489891-1A522AED-0ADE-406D-9003-9456C1BD4C0C

Q27489891-81D26738-EFA8-42A4-86E1-37A31CA02793

Q27489891-F51B6D85-FCBF-4137-A3E4-AEC459A9490B

P932

Q27489891-1634B706-DEE2-4195-9BAC-75D044330DCB

P3181

P356

J.SBI.2009.05.004

P1433

Current Opinion in Structural Biology

P1476

Neutralizing ebolavirus: struc ...... antibodies targeted against it

@en

P2093

Jeffrey E Lee

http://www.w3.org/2001/XMLSchema#string

P2860

C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans

Tyro3 family-mediated cell entry of Ebola and Marburg viruses

Structural basis of viral invasion: lessons from paramyxovirus F

Viral membrane fusion

Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme

Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution

Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G

Structure of the Ebola fusion peptide in a membrane-mimetic environment and the interaction with lipid rafts

Complex of a Protective Antibody with Its Ebola Virus GP Peptide Epitope: Unusual Features of a Vλx Light Chain

Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor

P304

408-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1623994

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.SBI.2009.05.004

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Erica Ollmann Saphire

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26323823

http://www.w3.org/2001/XMLSchema#string

P698

19559599

http://www.w3.org/2001/XMLSchema#string

P921

structural biology

P932

2759674

http://www.w3.org/2001/XMLSchema#string